SCHEMBL21473965

SCHEMBL21473965

CCn1c(=O)cc(N2CCOCC2)c2cc(NC(=O)CNCC(=O)c3ccccc3)ccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.51
ALDH1A1 P00352 8/20 0.51
KDM4E B2RXH2 8/20 0.51
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
MAPK1 P28482 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
NPY5R Q15761 4/20 0.50
LMNA P02545 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
HPGD P15428 3/20 0.48
GAA P10253 3/20 0.44
HTT P42858 1/20 0.44
USP2 O75604 1/20 0.44
POLB P06746 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20183704 0.90 MAPT (0.48) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL21549485 0.88 MAPT (0.47) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL20195131 0.81 ALDH1A1 (0.44) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL20183732 0.81 ENPP2 (0.47) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL23253945 0.80 MAPT (0.45) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL20183776 0.78 KMT2A (0.61) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL20354153 0.78 KMT2A (0.46) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL20195221 0.77 MEN1 (0.47) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL20183871 0.73 KDM4E (0.42) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL20183852 0.72 PRKDC (0.47) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987349-B2 Antitumor agent and bromodomain inhibitor BRD4, BRD1, BRD3 MAPT 3928/4885ALDH1A1 3243/4885KDM4E 1027/4885
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR BRD4, BRD1, BRD3 MAPT 3928/4885ALDH1A1 3243/4885KDM4E 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.